1. Home
  2. BOLT vs ADVB Comparison

BOLT vs ADVB Comparison

Compare BOLT & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

N/A

Current Price

$4.02

Market Cap

10.5M

Sector

Health Care

ML Signal

N/A

ADVB

Advanced Biomed Inc.

HOLD

Current Price

$6.90

Market Cap

8.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOLT
ADVB
Founded
2015
2014
Country
United States
United States
Employees
N/A
31
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
8.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BOLT
ADVB
Price
$4.02
$6.90
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
24.9K
10.1K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,695,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$133.33
N/A
P/E Ratio
N/A
$1.26
Revenue Growth
0.07
N/A
52 Week Low
$3.75
$0.19
52 Week High
$7.20
$9.42

Technical Indicators

Market Signals
Indicator
BOLT
ADVB
Relative Strength Index (RSI) 51.84 59.89
Support Level $3.90 $3.95
Resistance Level $4.41 $7.64
Average True Range (ATR) 0.23 0.84
MACD 0.08 0.24
Stochastic Oscillator 72.22 47.49

Price Performance

Historical Comparison
BOLT
ADVB

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: